Octreotide vs Somatostatin
The body's own hormone brake vs its long-acting synthetic analog — the pair behind suppression testing and excess-hormone research. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.
Octreotide
ApprovedOctreotide is a man-made medicine that acts like a hormone found naturally in the body. It is used by doctors to treat specific health problems, mostly those involving growth issues or tumors.
Somatostatin
ApprovedAlso: Somatostatin-28 (1-14) (Human, Rat, Mouse, Porcine) - Phoenix Pharmaceuticals, Inc, Somatostatin (Human, Rat, Mouse, Porcine) - Phoenix Pharmaceuticals, Inc
Somatostatin is a natural hormone found in the body that acts like a brake pedal for many other systems. It is produced in the brain, the stomach, and the pancreas.
At a Glance
| Octreotide | Somatostatin | |
|---|---|---|
| Research status | Approved | Approved |
| Highest-tier evidence | Peer-reviewed study | Peer-reviewed study |
| Research citations | 2 | 11 |
| Dosing routes | SubQ | SubQ |
| Receptor targets | — | — |
| Half-life | — | — |
| Known side effects | 121 | 55 |
Research Areas
Top preclinical research areas — cited studies for each.
Octreotide
- Octreotide decreases the incidence of pancreatic cancer and metastatic disease
- COX-2 inhibitor reduces pancreatic cancer and prevents intraductal papillary carcinoma
- Octreotide decreases incidence of pancreatic cancer and metastatic disease
- COX-2 inhibitor reduces pancreatic cancer incidence and prevents intraductal papillary carcinoma
- Propranolol demonstrates a cancer-protective effect against PDAC
Somatostatin
- SSTR antagonists proposed as adjuncts to insulin in diabetes therapy to prevent insulin-induced hypoglycaemia
- SGLT2 inhibitors (dapagliflozin) suppress insulin-induced somatostatin secretion, antagonising insulin's hypoglycaemic effect
- Somatostatin lowers plasma insulin and glucagon concentrations
- Reducing hyperglucagonemia via somatostatin (with insulin replacement) normalizes sepsis-induced elevated endogenous glucose production
- BDNF produces antidepressant effects in behavioral models of depression
How People Use It
Reported routines — research only, not medical advice.
Octreotide
- SubQ — 30 mg
- SubQ — Intravenous
- SubQ — Monthly injections
- SubQ — Not specified
- SubQ — 40 mg to 80 mg daily (20 mg twice daily)
- SubQ — Monthly injections
Somatostatin
- SubQ — Not specified
- SubQ — Radiolabelled somatostatin analogue administered for imaging
- SubQ — 100 nmol/l
The Evidence
Key studies — click through to verify each on PubMed.
Octreotide
2 sourced studies
- Source
(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
2024 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Somatostatin
11 sourced studies
- Source
Somatostatin | C76H104N18O19S2 | CID 16129706 - PubChem
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Inhibitory effect of somatostatin on inflammation and nociception.
2006 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
RecName: Full=Somatostatin; AltName: Full=Growth hormone release-inhib - Protein
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
2007 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Decision Guide
How to Choose
Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.
Source Octreotide
Shop OctreotideSource Somatostatin